Bionure is a clinical stage R&D company developing first-in-class small molecule drug candidates for the treatment of neurodegenerative diseases, that benefit from treatment options with limited efficacy. Our lead candidate, BN201, has shown compelling evidence of neuroprotective and remyelinating activity in several animal models and is completing a Phase 1 clinical study.
Bionure develops neuroprotectant agents to treat neurodegenerative diseases, primarily focusing on rare ophthalmologic diseases as Acute Optic Neuritis (AON) and Neuromyelitis Optica (NMO). Patients affected by these rare ophthalmological diseases may become blind or, in severe cases of NMO, even die.
The lead compound developed by Bionure, BN201, has demonstrated neuroprotective activity and stimulates remyelination. Both actions combined make it a promising solution for AON and NMO patients and open a research pathway to treat other neurodegenerative diseases such as Multiple Sclerosis (MS).
Bionure’s main candidate BN201 promotes nerve and brain natural repair by enhancing remyelination and neuroprotection. This new chemical entity (NCE) is a first-in-class selective SGK2 agonist.
SGK, which is expressed in the nerve tissue, is an intracellular serine/threonine kinase that plays a crucial role in the response of neurons to stress and its survival.
BN201 promotes cell survival and endogenous natural repair through activating SGK-mediated FOXO3 translocation from cell nucleus to cytoplasm. The translocation of protein FOXO3 out of the nucleus shuts-off the transcription of apoptotic genes, therefore promoting survival.